Pyrazolic compounds represent a large source of anticancer compounds, based on the choice of the scaffold
structure, the nature of the substituents and the sites of coordination. Here, we discuss our recent progresses in identifying
new active molecules from a synthetic library of 14 nitrogen compounds. All these compounds exert antiproliferative activity
against breast and colorectal cancer cell lines with varying IC50 values (the half-maximal inhibitory concentration,
which is a measure of the effectiveness of a compound in inhibiting biological or biochemical function). We found a onelog
order difference in activity among the different tested compounds. The most active compound 7 showed an IC50 values
equal to 8.5µg/ml in both MDA-MB 231(breast cancer) and LOVO (colorectal cancer) cell lines.
Keywords: Anti-cancer, LOVO, MDA-MB231, MTT assay, Normoxie conditions and drug design, Pyrazole.
Rights & PermissionsPrintExport